Thursday, Bahrain’s Ministry of Health approved the emergency use of the COVID-19 medication Sotrovimab.

The health ministry said that the “Sotrovimab-VIR-7831” develops monoclonal antibodies and will be used to treat infected adults and adolescents with mild to moderate coronavirus symptoms.

According to the ministry, the medication offers the prospect of reducing hospitalization for more than 24 hours and fatalities by as much as 85 percent when administered to patients as an early treatment for COVID-19.

June 17, Abu Dhabi received its first shipment of the coronavirus Sotrovimab medication, becoming the first city globally to receive it.

The UAE Ministry of Health and Prevention approved the emergency use of Sotrovimab in May.

May 26, the US Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy Sotrovimab for the treatment of mild-to-moderate coronavirus in adults and adolescents (aged 12 years and above and weighing at least 40 kg) who do not require supplemental oxygen therapy.